Novavax Inc. (NASDAQ:NVAX) does about 8.24M shares in volume on a normal day but saw 5660883 shares change hands in Friday trading. The company now has a market cap of 8.77B USD and an enterprise value of about $8.59B. Its current market price is $137.62, marking a decrease of -3.85% compared to the previous close of $143.13. The 52 week high reached by this stock is $189.40 whilst the lowest price level in 52 weeks is $3.54. The script in recent trading has seen the stock touch a high of $145.80 and a low of $133.30.
Novavax Inc. (NVAX) has a 20-day trading average at $150.47 and the current price is -27.34% off the 52-week high compared with 3787.57% distance from its 52-week low. The 50-day simple moving average of the closing price is $115.96 and its 200-day simple moving average is $40.10. If we look at the stock’s price movements over the week, volatility stands at 7.90%, which increases to 10.01% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 49.51 to suggest the stock is neutral.
5 analysts observing the Novavax Inc. (NVAX) stock have set the 12-month price targets for the company’s shares at between $105.00 and $290.00. The consensus objective for the share price is $227.60, suggesting that the stock has a potential upside of 39.53% over the period. The median price target is 46.45% away from the current levels at $257.00.
FactSet Research has provided data showing that 5 brokerages have issued ratings for the stock. 0 analysts have rated it as a sell, while 0 advise that it is a overweight. 3 analysts have rated it as a buy and 2 have advised that investors hold their positions. The consensus recommendation rating is Overweight and Wall Street’s advice is for investors to Moderate Buy the stock.
The company shares received a number of brokerage firm price updates over the past month, with the latest being on August 06, 2020 when H.C. Wainwright reiterated the stock to “Buy” and issued a price target of between $132 and $290. JP Morgan upgraded the stock to “Overweight” from Neutral on August 05, 2020 at a price target of $275. Ladenburg Thalmann downgraded its price target at $105.
The current price level is -8.43%, 20.62%, and 248.95% away from its SMA20, SMA50, and SMA200 respectively, with the NVAX price moving above the 50-day SMA on August 21. Novavax Inc. (NVAX) stock is down -6.07% over the week and -1.41% over the past month. Its price is 3357.79% year-to-date and 1975.72% over the past year.
The stock last released its quarterly earnings report for quarter ended 6/29/2020, with the company’s earnings per share (EPS) of -$0.3 above consensus estimates by $0.12. The company’s next earnings report is expected on 11/04/2020, with forecasts estimating quarterly EPS at $1.83 and $9.08 for whole year. NVAX’s earnings per share are forecast to grow by 264.80% this year and 139.50% over next year. Expected sales for next quarter are $893.45 million, which analysts say will come at $1.17 billion for the current fiscal year and next year at $2.74 billion. In addition, estimates put the company’s current quarterly revenue at an average of $237.06 million.
Its 12-month price target is $257.00. To reach the target analysts have set, the stock logically needs to grow 39.53 percent from here. Of course, the average price target is just what the average analysts believe a stock will be worth in the next 52 weeks, and is only one metric. There are analysts with lower targets than the average, including one bearish Wall Street research firm advocating investors to wait for the price to pull back to $105.00, given the recent momentum. And then, on the bullish side of things, one analyst is expecting the stock to peak at $290.00.
Outstanding shares total 58.62M with insiders holding 0.36% of the shares and institutional holders owning 13.89% of the company’s common stock. The company has a return on equity of 173.30%. The forward price to earnings ratio is 6.33. The beta has a value of 1.69. Price to book ratio is 43.69 and price to sales ratio is 174.71.
According to a U.S. Securities and Exchange Commission filing, Vanguard Total Stock Market Index has reduced its position in Novavax Inc. (NVAX) to 1,696,725 shares, mirroring a recent drop by -0.40%. Vanguard Total Stock Market Index dumped 6805.0 shares of Novavax Inc. common stock bringing its total worth to about $242.8 million at the end of recent close, SEC documents show. Vanguard Total Stock Market Index isn’t the only investment manager who changed stakes and is followed by SPDR S&P Biotech ETF, which sold off 12768.0 shares to end up with 1,274,555 shares worth $182.39 million. iShares Russell 2000 ETF cut their holdings by -4.47% in the company over the course of the most recent quarter. It now holds a 2.07% position in Novavax Inc. thanks to 1.2 million shares amounting to $171.92 million.